Chemo no longer option trading
Patient treatment preferences are increasingly being used to inform health care decision making. This discrete choice experiment assessed how chemo no longer option trading perceive the risks and benefits of hypothetical treatment options for metastatic castrate-resistant prostate cancer mCRPC. Treatment attributes for inclusion were identified through a review of the literature and product labels.
Expert interviews confirmed clinical appropriateness and patient relevance of the attributes, which included effectiveness delay in months before chemotherapysteroid use, possible drug interactions additional hospital visits for monitoringfogginess effects on cognition and memoryfatigue extreme tirednessfood restrictions, and bone pain.
Data were analyzed using a conditional logit chemo no longer option trading, with odds ratios ORs used to indicate preference for attributes, and tradeoff measures TOM were estimated using the ratio of coefficients.
They also preferred treatments that were associated with the lowest risk of fogginess OR, 2. Participants preferred to use steroids under advice from a physician OR, 1. Food restrictions related to taking medication were not a significant concern for participants. TOM results indicated that large tradeoffs in effectiveness, fogginess, and fatigue are required for patients to prefer a treatment with uncontrolled bone pain that is very difficult to live with.
Men with mCRPC consider a wide range of factors when making decisions regarding their treatment. They showed a strong preference for treatment associated with better control of bone pain. They also placed value on treatments that could delay the need for chemotherapy, and they preferred to avoid side effects such as cognition and memory loss, and extreme tiredness.
TOMs highlighted the importance of symptom control, even compared with potential side effects. An understanding of the degree to which patients value the attributes associated with various treatment options will assist chemo no longer option trading and health care professionals when making decisions regarding the management of men with mCRPC. Under a Creative Commons license. Abstract Purpose Patient treatment preferences are increasingly being used to inform health care decision making.
Methods Treatment attributes for inclusion were identified through a review of the literature and product labels. Implications Men with mCRPC consider a wide range of factors when making decisions regarding their chemo no longer option trading.
Recommended articles Citing articles 0. Published by Elsevier Inc.